Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.

Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.

Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.